ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
59,510.93
0.66%
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs Yen
153.011
-0.03%
Brent Oil
83.53
-0.12%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) ニュース

VSTM Verastem Inc

10.36
0.00 (0.00%)
プレマーケット
最終更新日： 17:09:53
15分遅延
名称 銘柄コード 市場 種別
Verastem Inc VSTM NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
Upgrade Icon
0.00 0.00% 10.36 17:09:53
始値 安値 高値 終値 前日終値
10.36
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1905:05BWVerastem Oncology Announces Appointment of John Hayslip,..
2024/4/0420:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
2024/3/1820:00BWGlobal Patient Survey Results Reveal Significant Negative..
2024/3/1505:05BWVerastem Oncology Reports Fourth Quarter and Full Year 2023..
2024/3/1206:07EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
2024/3/1120:30BWVerastem Oncology Announces Multiple Oral Presentations at..
2024/3/0607:27BWVerastem Oncology Receives Orphan Drug Designation from FDA..
2024/3/0606:30BWVerastem Oncology Announces Preclinical Presentations for..
2024/2/0906:22EDGAR2Form SC TO-I - Tender offer statement by Issuer
2024/2/0223:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/3006:01EDGAR2Form 8-K - Current report
2024/1/2921:00BWVerastem Oncology Outlines Key 2024 Strategic Priorities and..
2024/1/1921:54EDGAR2Form 8-K - Current report
2024/1/1906:00BWVerastem Oncology Granted Fast Track Designation for..
2024/1/1121:00BWVerastem Oncology to Participate in the B. Riley Securities..
2024/1/1006:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0906:02EDGAR2Form 8-K - Current report
2024/1/0521:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
2023/12/2906:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2206:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2106:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2106:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/2006:01EDGAR2Form DEF 14A - Other definitive proxy statements
2023/12/1821:00BWVerastem Oncology Selects Oral KRAS G12D Inhibitor..
2023/12/1321:00BWVerastem Oncology Announces Initiation of a Confirmatory..
2023/12/0906:10EDGAR2Form PRE 14A - Other preliminary proxy statements
2023/11/2114:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/11/1321:00BWNew Healthcare Professional Component of Let’s Talk About..
2023/11/0907:01EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/11/0906:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0906:12BWVerastem Oncology Reports Third Quarter 2023 Financial..
2023/11/0721:00BWFirst-Of-Its-Kind, Multi-National Patient Impact Survey..
2023/11/0621:00BWVerastem Oncology Announces Efficacy and Safety Data of..
2023/10/2805:41EDGAR2Form 8-K - Current report
2023/10/2705:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/2705:05BWVerastem Oncology Strengthens Executive Leadership Team with..
2023/10/1905:50BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
2023/10/1501:30BWVerastem Oncology Announces Initial Results of RAMP 203..
2023/10/1105:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/0620:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
2023/9/2903:27EDGAR2Form 8-K - Current report
2023/9/2903:15BWVerastem Presents Avutometinib and Defactinib Combination..
2023/9/2605:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/2105:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/2105:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/1305:08EDGAR2Form 8-K - Current report
2023/9/0520:00BWVerastem Oncology to Participate in Upcoming Investor..
2023/8/2820:00BWVerastem Oncology Enters Discovery and Development..
2023/8/0905:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0905:05BWVerastem Oncology Reports Second Quarter 2023 Financial..

最近閲覧した銘柄

NASDAQ
VSTM
Verastem
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有